• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum
In this study, a 35-year-old Indian man with an undiagnosed progressive axial spondyloarthropathy (i.e., AS) is reported presenting with acute-onset longitudinally extensive transverse myelitis, a clinical subset of NMOSD. Neuromyelitis optica spectrum disorder (NMOSD), a primary demyelinating disorder of the central nervous system (CNS), is an autoimmune astrocytopathy against foot processes of aquaporin-4 (AQP4) water channels, which manifests with optic neuritis, longitudinally extensive transverse myelitis (LETM), area-postrema syndrome, brainstem syndrome diencephalic syndrome, and cerebral syndrome.1-4 Ankylosing spo...
Source: Herpes - July 22, 2022 Category: Infectious Diseases Authors: Ritwik Ghosh Md Devlina Roy Mois és León-Ruiz Shambaditya Das Souvik Dubey Juli án Benito-León Source Type: research

Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
IDCases. 2022 Jul 13;29:e01563. doi: 10.1016/j.idcr.2022.e01563. eCollection 2022.ABSTRACTAs a result of the COVID-19 pandemic, mRNA vaccination has become widespread. Recently, it has been suggested that instances of herpes zoster increase following mRNA COVID-19 vaccination. Herein, we describe the first case of zoster sine herpete (ZSH) after mRNA vaccination for COVID-19. A 60-year-old Japanese immunocompetent man presented with fever, fatigue, headache, cervical pain, and lumbar pain, which developed after receiving a second dose of BNT162b2 mRNA COVID-19 vaccination. Whereas most symptoms improved with symptomatic tr...
Source: Herpes - July 20, 2022 Category: Infectious Diseases Authors: Ryutaro Tanizaki Yayoi Miyamatsu Source Type: research

Molecules, Vol. 26, Pages 1132: Advances and Perspectives in the Management of Varicella-Zoster Virus Infections
eck Varicella-zoster virus (VZV), a common and ubiquitous human-restricted pathogen, causes a primary infection (varicella or chickenpox) followed by establishment of latency in sensory ganglia. The virus can reactivate, causing herpes zoster (HZ, shingles) and leading to significant morbidity but rarely mortality, although in immunocompromised hosts, VZV can cause severe disseminated and occasionally fatal disease. We discuss VZV diseases and the decrease in their incidence due to the introduction of live-attenuated vaccines to prevent varicella or HZ. We also focus on acyclovir, valacyclovir, and famciclovir (FDA app...
Source: Molecules - February 20, 2021 Category: Chemistry Authors: Graciela Andrei Robert Snoeck Tags: Review Source Type: research

Herpes Zoster Vaccine
This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines.PMID:31105132 | DOI:10.2222/jsv.68.21
Source: Uirusu. Journal of Virology - May 21, 2019 Category: Virology Authors: Daisuke Watanabe Source Type: research

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Recombinant Zoster Vaccine (Shingrix ® ): A Review in Herpes Zoster
AbstractShingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein  E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged  ≥ 50 years. In the pivotal trials in adults aged ≥ 50 years (ZOE-50) and ≥ 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged ≥ 70 years. In patients with brea...
Source: Drugs and Aging - October 29, 2018 Category: Geriatrics Source Type: research

Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies.
Abstract Population aging is a worldwide phenomenon with significant and manifold impacts on society. Advanced age correlates with the onset of frailty. In this vulnerable state, the immune response is weakened and a higher susceptibility to infectious diseases is observed. The present narrative review aims to cover the topic of herpes zoster (HZ) and its complications in frail populations. The lifetime risk of developing HZ is estimated at about 20-30%, and the risk increases with age. In older people, HZ can lead to the inability to recover the lifestyle, the interests, and the level of activity that existed bef...
Source: Aging Clinical and Experimental Research - May 2, 2018 Category: Geriatrics Authors: Zorzoli E, Pica F, Masetti G, Franco E, Volpi A, Gabutti G Tags: Aging Clin Exp Res Source Type: research

Herpes Zoster Vaccine.
This article aimed to review the epidemiology, pathophysiology and complications of herpes zoster and mention the efficacies and problems of the live-attenuated and the new recombinant herpes zoster vaccines. PMID: 31105132 [PubMed - in process]
Source: Uirusu. Journal of Virology - December 31, 2017 Category: Virology Authors: Watanabe D Tags: Uirusu Source Type: research